A very small Stanford study of continuous glucose monitoring joining Apple’s HealthKit, Dexcom’s glucose monitor and Epic’s EHR/PHR system found improved glycemic control in pediatric patients as a result.
Partners’ digital health guru Joseph Kvedar ponders another, bigger recent connected health trial that proved disappointing and finds a likely culprit in poor integration of the initiative into practices (which is to say, lousy communication between doctors and telemonitoring nurses).
A comScore white paper says smartphone apps account for nearly half of all digital media time spent and that “Consumers significantly accelerated their use of mobile devices for both shopping and purchase activity” in 2015.
Also going into effect this month: onerous new Medicare payment rules that reimburse hospitals for hip and knee replacements only after 90 days, putting pressure on them to ensure a smooth home recovery, lest they be stuck with the bill for an expensive stay in a rehab facility. One more way patient engagement is becoming paramount for hospitals and health systems.
Interbrand Health has calculated the top ten pharma brands and their brand value. Number One: Pfizer, with a brand value of nearly $20 billion, per Interbrand.
Bayer, meanwhile, has extended its iconic aspirin branding across all products and is making a big push into social media. The drug maker, with its trove of OTC brands, “has doubled its social media staff, started an Instagram page, added U.S. content to its Facebook page and increased its Twitter posts sevenfold, with product and other news, quizzes and links to sites offering product coupons and tips on related disorders.”
The American College of Physicians issued a broad position paper on drug pricing, calling for increased transparency around pricing, R&D spend and advertising, and urging that regulators hold the line on patent exclusivity.
Speaking of pricing, Pfizer got hit with a Yes Men-esque April Fools’ Day prank as someone spoofing Pfizer PR announced that the company would no longer hike drug prices. (The Real) Pfizer soon posted a statement flagging the hoax, but not before the Washington Post ran with the hoaxers’ story.
Sanofi/Regeneron’s promising atopic dermatitis drug dupilumab, an anticipated blockbuster, cleared some hurdles with trial results meeting targets, cheering investors.
A group of legal scholars is calling for a federal ban on employers hiring or firing employees based on health info and giving consumers access to (and control over) what health data is collected on them by services like Castlight.
Hackers have long been raiding patient records for Social Security numbers and the like, but last week, hackers inserted “ransomware” – pay us in bitcoin or your records get it – into the EHR of a big Washington-area health system.
Here’s a very critical look at prescription sleep aids – in particular, Merck’s Belsomra – and the big advertising campaigns behind them. The angle of the piece aside, it includes an interesting history of the fairly recent birth of DTC advertising as we know it.